We are pioneering a new class of medicine we call endobody vaccines that are fully synthetic and train the body to safely and efficiently treat and prevent neurological disease.
We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, CTE and other neurological diseases.
We envision a world where neurodegenerative diseases are prophylactically eradicated.
By The Numbers
80 years ago, it was polio. Today, our epidemic is Alzheimer’s.
CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD
ANNUAL COST TO THE WORLD
Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop vaccines to treat and ultimately prevent Alzheimer’s and other neurological diseases.
We aren’t your average vaccine company.
We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading endobody vaccine technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active vaccine against Alzheimer’s.
February 7, 2019 -
Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.Read More
January 30, 2019 -
For two decades, biotech companies trying to tackle Alzheimer’s disease have had little success. While vaccines have often shown promise for certain patients, they’ve come with devastating side effects for others—brain swelling, for example—because researchers haven’t been able to reliably keep patients’ immune systems from kicking into overdriveRead More